Navigation Links
STALLERGENES : Sales Guidance Exceeded : EUR193 Million, up 13%
Date:1/14/2010

    ANTONY, France, January 14 /PRNewswire-FirstCall/ --
    - Strong Sales Growth in Q4: Up 15%

    Million EUR              2008           08/07    2009              09/08
                             MEUR   %Sales  Var.%    MEUR     %Sales   Var.%
    Southern Europe (1)        36.4     73      14      42.4        74    16
    Other EU countries (2)     11.3     23      17      13.1        23    16
    Other markets               2.0      4      45       1.5         3   (25)

    SLIT                       40.4     81      17      48.5        85    20
    SCIT                        7.5     15       6       6.8        12   (10)
    Other products              1.8      4      32       1.7         3    (5)

    Total Q4 sales             49.7    100      15      57.0       100    15

    Million EUR              2008           08/07    2009              09/08
                             MEUR   %Sales  Var.%    MEUR     %Sales   Var.%
    Southern Europe (1)       124.9     73      14     138.6        72    11
    Other EU countries (2)     38.5     23      18      47.6        25    24
    Other markets               7.5      4      38       6.7         3   (11)

    SLIT                      137.9     81      18     160.0        83    16
    SCIT                       26.3     15       6      25.9        13    (2)
    Other products              6.7      4      16       6.9         4     4

    Cumulated sales           170.9    100      16     192.8       100    13
    (1) Portugal, Spain, France, Italy, Greece; (2) Switzerland
    included

Sales growth and financial position

Sales growth sped up over the fourth quarter to 15%, 3 percentage points higher than that of third quarter 2009. The markets of Northern Europe ("Other EU") and the sublingual route drove this progression but the markets of Southern Europe had an encouraging recovery in growth over the last quarter. Other markets were affected by a negative basis effect due to the strong growth achieved in 2008.

Organic growth, after restatement for foreign exchange effects stood at 13% over the quarter and 12% over the full year.

As a consequence, results for the year will markedly improve: operating profit and net profit as a percentage of sales should remain close to the levels achieved in 2008 (16% and 11%, respectively). The Company had a positive net cash position at the end of the financial year.

The comprehensive 2009 results will be published on 16 March 2010 after close of trading.

As for 2010, the Group is currently expecting significant growth and a further improvement in its results due to the limitation put on R&D expenses.

Significant 4th quarter transactions and events

Following the mutual recognition procedure, Oralair(R) (immunotherapy tablet for grass pollen) was granted a marketing authorisation in 22 European countries in its adult and paediatric indications on 27 November 2009.

The outstanding results of the study devoted to showing the long-term sustained effect of Oralair(R) were announced on 7 December 2009. They significantly confirmed the clinical relevance of Oralair(R). This study is being continued with a view to demonstrating the persistence of the effect after completion of the treatment (carry-over effect), which should be the subject of an announcement at the end of 2010.

The Oralair(R) phase III clinical study in the US was completed in good conditions. Talks are ongoing with the FDA on statistical analysis matters. These exchanges have no impact on the results of the study but must be concluded before the database is opened for analysis. Consequently, the delivery of the preliminary results will take place in a few weeks.

The authorisation to carry out a Phase III clinical study on children for Actair(R) (immunotherapy tablet for dust mites) on 450 patients has been granted in Europe and patients are being recruited. The preliminary results should be published in mid-2011.

The presentation of the clinical results obtained in 2009 and at the start of 2010 will be the subject of a specific meeting, to be organised shortly.

About Stallergenes

Stallergenes is a European biopharmaceutical laboratory specialising in treatments by immunotherapy for the prevention and treatment of allergy-related respiratory conditions, such as rhino conjunctivitis, rhinitis and allergic asthma. Stallergenes is ranked seventh among French pharmaceutical laboratories. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates 21% (gross) of its sales to its Research and Development activities, which are primarily directed at developing a new therapeutic range enabling the provision of immunotherapy treatments by sublingual tablets.

Stallergenes realised 2009 sales of EUR 193 million, with over 500,000 patients treated with Stallergenes desensitisation products.

    Euronext Paris (Compartment B).
    SBF 120 index.
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP

For further financial information, please visit our website: http://www.stallergenes.com

SOURCE Stallergenes


'/>"/>
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe
2. STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial
3. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
4. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
5. Stallergenes : Investor Meeting: Webcast is Available
6. STALLERGENES: 2008: Strong Performance
7. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
8. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
9. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
10. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
11. Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... to enabling healthier lives through the development of innovative ... of the United States denied ... that the claims of Sequenom,s U.S. Patent No. 6,258,540 ... eligibility criteria established by the Supreme Court,s Mayo Collaborative ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
Breaking Biology Technology:
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):